Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
14.79
+0.01 (0.07%)
May 19, 2025, 4:00 PM - Market closed
Edgewise Therapeutics Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Edgewise Therapeutics stock ranges from a low of $14 to a high of $52. The average analyst price target of $40.13 forecasts a 171.33% increase in the stock price over the next year.
Price Target: $40.13 (+171.33%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Edgewise Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 5 | 5 | 5 | 6 | 5 | 5 |
| Hold | 0 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $43 | Buy | Maintains | $43 | +190.74% | Apr 21, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $56 → $52 | Buy | Maintains | $56 → $52 | +251.59% | Apr 3, 2025 |
| Scotiabank | Scotiabank | Buy → Hold Downgrades $50 → $14 | Buy → Hold | Downgrades | $50 → $14 | -5.34% | Apr 3, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $51 | Buy | Maintains | $51 | +244.83% | Apr 2, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $50 | Buy | Initiates | $50 | +238.07% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
n/a
from 516.72M
Revenue Next Year
n/a
EPS This Year
-1.90
from -1.45
EPS Next Year
-2.09
from -1.90
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 33.6M | 111.2M | ||
| Avg | n/a | 5.8M | 44.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,812.3% | ||
| Avg | - | - | 671.6% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.68 | -1.51 | -1.46 | ||
| Avg | -1.90 | -2.09 | -2.12 | ||
| Low | -2.05 | -2.44 | -2.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.